Qianjiang Pharmaceutical

Hubei Qianjiang Pharmaceutical Co., Ltd. is located in Qianjiang City, a beautiful area on the Jianghan Plain and a "Star City" of China. It is one of the earliest national production bases for ophthalmic drugs and was among the first batch of listed companies in the ophthalmic pharmaceuticals industry. The company has total assets of 1.3 billion yuan and more than 1,000 employees. Subsidiaries include a raw material medicine factory and a plastic packaging factory. It also holds controlling interest in Hubei Dongsheng Pharmaceutical Co., Ltd., and a stake in Xinjiang Xinte Medicine Ethnic Pharmaceutical Co., Ltd.The company boasts leading modern plant facilities in China and excellent production conditions. It consistently focuses on seizing the technological high ground as the foundation for its success. To ensure forward-looking technology, the company places great emphasis on investment in research and development, strengthening technological innovation and new product development. It has established a robust R&D center with a strong technical team, including the Qianjiang Pharmaceutical Postdoctoral Research Station, forming a fast-moving and self-sustaining technological innovation system from research to development and production. The company aims at the forefront of international pharmaceutical science and technology, launching 3-4 new drugs annually. Currently, it has obtained new drug certificates for 23 new drugs and achieved series and large-scale production of many products. The company implements a customer-first 4C marketing model, gradually establishing a high-quality, high-efficiency marketing system covering seven major dosage forms and over 150 varieties, including eye drops, injections, freeze-dried powders, tablets, capsules, granules, and chemical raw materials. At the same time, it vigorously promotes office responsibility systems, regional agency systems, and pharmaceutical bidding systems, achieving good results and steadily increasing market share for its products.